FDA Expands Guselkumab Label in PsA - Top_Thought_Leaders - MDSpire

FDA Expands Guselkumab Label in PsA

Phase 3b APEX findings support the addition of structural joint damage inhibition data to the prescribing information.

  • By

  • Kathryn Wighton

  • May 29, 2026

  • 2 min

Share

Top Thought Leaders in Rheumatology

Brief introduction explaining scope and methodology.

Original Source(s)

FDA Expands Guselkumab Label in PsA

  • by Kathryn Wighton

  • May 29, 2026

Related Content

Semaglutide Use Linked to Erythromelalgia Remission

Case details diagnostic workup and rapid symptom resolution following GLP-1 receptor agonist initiation.

Wearables May Boost T2D Mobility

Outpatient intervention combined physiotherapist counseling with wrist-worn activity monitoring.

A Narrative Review: Do Systemic Drugs Used in the Treatment of Psoriatic Disease Affect Alzheimer’s Disease?